Dyne Therapeutics (NASDAQ:DYN) Given New $43.00 Price Target at JPMorgan Chase & Co.

Dyne Therapeutics (NASDAQ:DYNGet Free Report) had its price target hoisted by equities researchers at JPMorgan Chase & Co. from $39.00 to $43.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 8.72% from the stock’s current price.

Several other research firms also recently issued reports on DYN. Chardan Capital lifted their price target on shares of Dyne Therapeutics from $31.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, May 21st. Jefferies Financial Group lifted their price target on shares of Dyne Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, May 20th. Oppenheimer reissued an “outperform” rating and issued a $47.00 price target on shares of Dyne Therapeutics in a research report on Monday, May 6th. HC Wainwright lifted their price objective on shares of Dyne Therapeutics from $36.00 to $48.00 and gave the stock a “buy” rating in a report on Monday, May 20th. Finally, Morgan Stanley began coverage on shares of Dyne Therapeutics in a report on Tuesday, April 30th. They set an “overweight” rating and a $40.00 price objective on the stock. One research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.11.

View Our Latest Research Report on Dyne Therapeutics

Dyne Therapeutics Stock Up 6.3 %

Shares of DYN stock opened at $39.55 on Tuesday. The company has a market cap of $3.46 billion, a price-to-earnings ratio of -9.96 and a beta of 1.07. Dyne Therapeutics has a 52 week low of $6.40 and a 52 week high of $39.60. The firm has a 50 day moving average of $31.68 and a 200-day moving average of $25.91.

Dyne Therapeutics (NASDAQ:DYNGet Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.81) EPS for the quarter, hitting the consensus estimate of ($0.81). Analysts anticipate that Dyne Therapeutics will post -3 earnings per share for the current year.

Insider Activity at Dyne Therapeutics

In related news, SVP Richard William Scalzo sold 1,590 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $30.23, for a total value of $48,065.70. Following the sale, the senior vice president now directly owns 115,105 shares in the company, valued at approximately $3,479,624.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Dyne Therapeutics news, COO Susanna Gatti High sold 10,163 shares of Dyne Therapeutics stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $35.33, for a total transaction of $359,058.79. Following the completion of the transaction, the chief operating officer now owns 148,792 shares of the company’s stock, valued at approximately $5,256,821.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Richard William Scalzo sold 1,590 shares of Dyne Therapeutics stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $30.23, for a total value of $48,065.70. Following the transaction, the senior vice president now directly owns 115,105 shares of the company’s stock, valued at approximately $3,479,624.15. The disclosure for this sale can be found here. In the last three months, insiders have sold 202,133 shares of company stock worth $6,500,387. Company insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Wetzel Investment Advisors Inc. purchased a new position in Dyne Therapeutics during the 1st quarter valued at about $28,000. Ameritas Investment Partners Inc. grew its holdings in shares of Dyne Therapeutics by 28.0% during the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock worth $167,000 after purchasing an additional 1,291 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Dyne Therapeutics by 355.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company’s stock worth $94,000 after purchasing an additional 5,541 shares in the last quarter. EntryPoint Capital LLC purchased a new position in shares of Dyne Therapeutics during the first quarter worth about $214,000. Finally, SG Americas Securities LLC purchased a new position in shares of Dyne Therapeutics during the fourth quarter worth about $172,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

(Get Free Report)

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

See Also

Analyst Recommendations for Dyne Therapeutics (NASDAQ:DYN)

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.